| 1 |
Furukawa T, Yoshimura A, Sumizawa T, et al. Angio-genic factor[J]. Nature, 1992, 356 (6371): 668.
|
| 2 |
叶钿均，张继民. 胸苷磷酸化酶表达与结直肠癌关系研究进展[J]. 中国肿瘤临床，2013，40(12):736-740.
|
| 3 |
King GL, Buchwald S. Characterization and partial pu-rification of an endothelial cell growth factor from human platelets[J]. J Clin Invest, 1984, 73 (2): 392-396.
|
| 4 |
Miyazono K, Okabe T, Ishibashi S, et al. A platelet factor stimulating the proliferation of vascular endothelial cells. Partial purification and characterization[J]. Exp Cell Res, 1985, 159 (2): 487-494.
|
| 5 |
Ishikawa F, Miyazono K, Hellman U, et al. Identifica-tion of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor[J]. Nature, 1989, 338 (6216): 557-562.
|
| 6 |
Yoshimura A, Kuwauru Y, Furukawa T, et al. Purific-ation and tissue distribution of human thymidine phosphorylase; high expression in lymphocytes, reticulocytes and tumors[J]. Biochem Biophy Acta, 1990, 1034 (1): 107-113.
|
| 7 |
Moghaddam A, Zhang HT, Fan TP, et al. Thymidine phosphorylase is angiogenic and promotes tumor growth[J]. Proc Natl Acad Sci U S A, 1995, 92 (4): 998-1002.
|
| 8 |
Seki N, Kodama J, Hongo A, et al. Vascular endothe-lial growth factor and platelet-derived endothelial cell growth factor expression are implicated in the angiogenesis of endometrial cancer[J]. Eur J Cancer, 2000, 36 (1): 68-73.
|
| 9 |
Arima J, Imazono Y, Takebayashi Y, et al. Expression of thymidine phosphorylase as an indicator of poor prognosis for patients with transitional cell carcinoma of the bladder[J]. Cancer, 2000, 88 (5): 1131-1138.
|
| 10 |
Giatromanolaki A, Koukourakis MI, Comley M, et al. Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer[J]. J Pathol, 1997, 181 (2): 196-199.
|
| 11 |
Saito H, Tsujitani S, Oka S, et al. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma[J]. Br J Cancer, 1999, 81 (3): 484-489.
|
| 12 |
Takahashi Y, Bucana CD, Liu W, et al. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells[J]. J Natl Cancer Inst, 1996, 88 (16): 1146-1151.
|
| 13 |
Liekens S, Bronckaers A, Pérez-Pérez MJ, et al. Tar-geting platelet-derived endothelial cell growth factor / thymidine phosphorylase for cancer therapy[J]. Biochem Pharmacol, 2007, 74 (11): 1555-1567.
|
| 14 |
Ignatescu MC, Gharehbaghi-Schnell E, Hassan A, et al. Expression of the angiogenic protein, platelet-derived endothelial cell growth factor, in coronary atherosclerotic plaques: in vivo correlation of lesional microvessel density and constrictive vascular remodeling[J]. Arterioscler Thromb Vasc Biol, 1999, 19 (10): 2340-2347.
|
| 15 |
Li W, Gigante A, Perez-Perez MJ, et al. Thymidine phosphorylase participates in platelet signaling and promotes thrombosis[J]. Circ Res, 2014, 115 (12): 997-1006.
|
| 16 |
Griffiths L, Dachs GU, Bicknell R, et al. The influen-ce of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor / thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo[J]. Cancer Res, 1997, 57 (4): 570-572.
|
| 17 |
Gotanda T, Haraguchi M, Tachiwada T, et al. Molecu-lar basis for the involvement of thymidine phosphorylase in cancer invasion[J]. Int J Mol Med, 2006, 17 (6): 1085-1091.
|
| 18 |
Zhu GH, Lenzi M, Schwartz EL. The Sp1 transcription factor contributes to the tumor necrosis factor-induced expression of the angiogenic factor thymidine phosphorylase in human colon carcinoma cells[J]. Oncogene, 2002, 21 (55): 8477-8485.
|
| 19 |
Schwartz EL, Wan E, Wang FS, et al. Regulation of expression of thymidine phosphorylase / platelet-derived endothelial cell growth factor in human colon carcinoma cells[J]. Cancer Res, 1998, 58 (7): 1551-1557.
|
| 20 |
肖永胜，周俭，樊嘉，等. 干扰素对肝癌细胞胸苷磷酸化酶表达和凋亡的双重影响[J]. 世界华人消化杂志，2009，17(35):3630-3634.
|
| 21 |
Blanquicett C, Gillespie GY, Nabors LB, et al. Induc-tion of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation[J]. Mol Cancer Ther, 2002, 1 (12): 1139-1145.
|
| 22 |
游伟，张继民，邹湘才，等. 结直肠癌肝转移组织中胸苷磷酸化酶表达[J]. 国际外科学杂志，2009，36(7):440-444.
|
| 23 |
Nozawa T, Enomoto T, Koshida Y, et al. Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer[J]. Dis Colon Rectum, 2004, 47 (12): 2093-2100.
|
| 24 |
Yasuno M, Mori T, Koike M, et al. Importance of thymidine phosphorylase expression in tumor stroma as a prognostic factor in patients with advanced colorectal carcinoma[J]. Oncol Rep, 2005, 13 (3): 405-412.
|
| 25 |
Rhodes A, Evans LE, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016[J]. Crit Care Med, 2017, 45 (3): 486-552.
|
| 26 |
Galley HF. Oxidative stress and mitochondrial dysfunc-tion in sepsis[J]. Br J Anaesth, 2011, 107 (1): 57-64.
|
| 27 |
Kofoed K, Andersen O, Kronborg G, et al. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study[J]. Crit Care, 2007, 11 (2): R38.
|
| 28 |
黄伟平，江稳强，胡北，等. 降钙素原对全身炎症反应综合征患者病情预后的判断价值[J]. 中华危重病急救医学，2012，24(5):294-297.
|
| 29 |
刘亚峰，闫春良，薛旗山，等. C反应蛋白在慢性阻塞性肺疾病急性加重期治疗前后的分析[J]. 江西医药，2012，47(9):791-792.
|
| 30 |
Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage[J]. Nat Rev Drug Discov, 2005, 4 (10): 854-865.
|
| 31 |
Jaimes F, De La Rosa G, Morales C, et al. Unfracti-oned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study)[J]. Crit Care Med, 2009, 37 (4): 1185-1196.
|
| 32 |
Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan[J]. Int J Hematol, 2016, 103 (3): 253-261.
|
| 33 |
Murata A, Okamoto K, Mayumi T, et al. The recent time trend of outcomes of disseminated intravascular coagulation in Japan: an observational study based on a national administrative database[J]. J Thromb Thrombolysis, 2014, 38 (3): 364-371.
|
| 34 |
Iba T, Yamada A, Hashiguchi N, et al. New therapeu-tic options for patients with sepsis and disseminated intravascular coagulation[J]. Pol Arch Med Wewn, 2014, 124 (6): 321-328.
|
| 35 |
Ogura H, Gando S, Saitoh D, et al. Epidemiology of severe sepsis in Japanese intensive care units: a prospective multicenter study[J]. J Infect Chemother, 2014, 20 (3): 157-162.
|
| 36 |
Kral JB, Schrottmaier WC, Salzmann M, et al. Platelet interaction with innate immune cells[J]. Transfus Med Hemother, 2016, 43 (2): 78-88.
|
| 37 |
Schrottmaier WC, Kral JB, Badrnya S, et al. Aspirin and P2Y12 inhibitors in platelet-mediated activation of neutrophils and monocytes[J]. Thromb Haemost, 2015, 114 (3): 478-489.
|